Source file signed link, expires in 15 minutes
Extracted text 18
Page 1
PT Diagnos Laboratorium Utama, Tbk (DGNS) Newsletter Q-3 Update Public Expose 11 December 2024
Page 2
3Q2024 Performance Highlight
Quarter Report Cumulative Report Key Notes
3Q 2024 9M 2024
Description Unit 3Q2023 3Q2024 % YoY 9M2023 9M2024 % YoY
Core Business in 9M2024
• Achieved 15% revenue growth and a 23% increase in Gross Profit Value,
PROFIT LOSS STATEMENT showing an improvement in Gross Profit Margin by 3%, from 45% to
Revenue IDR 35.903 42.310 18% 107.114 123.356 15% 48%. Revenue growth was product-driven, with 189 new products
launched in 2024, despite a decrease in the number of outlets during
COGS (exclude depreciation) IDR 20.013 22.507 12% 59.171 64.343 9% the year.
Gross Profit (Exlude Depreciation) IDR 15.890 19.803 25% 47.943 59.013 23% • Diagnos EBITDA & Net Profit recovered to a profit level compared to
Gross Profit Margin Percent 44% 47% 45% 48% 9M23, which recorded IDR -95 million in EBITDA. This improvement
was a result of efficiency initiatives in launching new products and
OPEX (exclude depreciation) IDR 15.138 16.424 8% 48.038 48.076 0% eliminating nonproductive outlets.
EBITDA IDR 752 3.379 349% (95) 10.937 11626%
Depreciation & Amortization IDR 3.650 3.656 0% 11.124 10.982 -1%
EBIT IDR (2.897) (277) -90% (11.219) (45) -100%
EBIT Margin Percent (8%) (1%) (10%) (0%)
Other Income IDR 230 187 -19% 1.019 361 -65%
Net Interest Expenses IDR (347) (602) 73% (614) (956) 56%
EBT IDR (3.015) (692) 77% (10.814) (640) 94%
Taxes IDR (102) - -100% (163) (1.109) 579%
Net Income/(loss) IDR (2.912) (692) 76% (10.651) 469 104%
NP Margin Percent (8%) (2%) (10%) 0%
Laboratories Product & Volume
Total Volume Test 175.207 206.509 18% 509.480 637.479 25%
Total New Product Launching Menu 64 189
Lab & Clinic Presence
Stand Alone Laboratories Outlet 5 5
Outlet Outlet 23 20
Total all Diagnos Outlet 28 25
Page 3
Company Overview
Page 4
DIAGNOSTIC PILLAR OF THE BMHS HEALTHCARE ECOSYSTEM
BMHS value of excellence and visionary medical
BMHS (Bundamedik) Group of Companies to form the most methodology are imparted as DGNS has been
comprehensive lifestyle health care provider in Indonesia strategically located within BMHS Business Unit
IVF Diagnostic Lab Established in 2007, PT Diagnos Laboratorium Utama
Clinics (“DGNS”) Tbk. Is one of the leading clinical laboratories
taking part as one of the BMHS (Bundamedik Healthcare
Specialty Emergency
System) Group companies which are focusing in delivering
Hospital Response high quality clinical diagnostics services that are consistent,
trustworthy and reliable to all partners and customers, with
strong experience and management expertise in clinical
laboratory. DGNS offer a wide range of laboratory services
Hospital Pharmacy that best suites in class facilities and infrastructure support.
Currently, DGNS have more than 500 types of test in its
arsenal and operates in more than 30 sites as both Stand
BIC Clinics
Dental
Clinic
Alone Laboratories and Hospital or Clinic Laboratories, in
Sumatera, Java, Bali and Sulawesi.
Medical
Tourism Physiotherapy
Board
Page 5
Extensive List Of Test Offered Within Our Integrated Lab
Ecosystem
Diagnos Institute
Excellent
Laboratory
Integrated Clinical
Laboratory Ecosystem
Diagnos focusing in delivering high quality clinical
diagnostics services that are consistent, trustworthy
and reliable to all partners and customers.
We offer a wide range integrated laboratory services
that best suites in class facilities and infrastructure
support.
Digital
Integration
Page 6
GENETICS PRODUCT AS SERVICES UMBRELLA TO CAPTURE
FUTURE MEDICINE OPPORTUNITY
Strong Uptrend on Genomic Testing Volume signaling a
growing demand on Genetic Testing Product
2,405
2,000
1,800 1,670
1,600
1,400
1,200 1,057
1,000 852
765
800 660 604
600
400 306
200
-
2019 2020 2021 2022 2023 3Q 2023 2Q 2024 3Q 2024
Diagnos Genomic is the leading clinical laboratory when it comes to the
service of reproductive genomics testing. Our team is equipped with strong
expertise in assisting patients for reproductive purposes and family planning.
DNAnswer serve as our service umbrella at Diagnos Genomics with the vision
of providing quality and reliable services through all genetic testing.
Page 7
DOMESTIC & INTERNATIONAL RECOGNITION ON DELIVERING CLINICAL LAB SERVICES Quality Management To provide quality services to customers, we continuously to innovate and are currently accredited by : 1. ISO 45001 : For Occupational Health & Safety Management System on Clinical Laboratory Services 2. ISO 15189 : For Clinical Laboratory Competence and Quality 3. ISO 9001 : Quality Management System 4. RS (SNARS 2012) : Diagnos in hospitals 5. ACHS International accreditation : Diagnos in hospitals
Page 8
Market Overview & Growth Strategies
Page 9
DIVE DEEPER INTO ONE OF THE FASTEST GROWING SERVICE
SEGMENTS IN HEALTHCARE SECTOR IN INDONESIA
INDONESIA CLINICAL LABORATORY MARKET SIZE GROWTH
From 3,7 Bn USD Market size, 43,8% of the diagnostics
market comes from Public Hospital Laboratory
3,710
3,345 Contribution To Market /
Provider Segment # of Key Players
2,981 Market Growth
15.5% 2,686
15.0% 2020
2,377
13.0%
Independent 17,9% / 7,23% 1,535 Laboratories
2,058
1,908 12.2% Laboratories 341 Mn USD / 1,9 Bn USD Prodia, Paramita, Diagnos
11.0% 10.9%
917 Laboratories
9.3% Private 37,9% / 10,42%
Hospital Lab 662 Mn USD / 1,9 Bn USD
Siloam, Bunda (Diagnos),
Mitra Keluarga
1,594 Laboratories
Public 43,8% / 9,14%
RSCM, RS Fatmawati, RS
Hospital Lab 766 Mn USD / 1,9 Bn USD Tarakan
2020 2021 2022 2023 2024 2025E 2026E
2020 2021 2022 2023 2024 2025E 2026E Source : Frost & Sullivan “Analysis of the Indonesian Clinical Laboratories
Market”
Source : Kent Research “Analysis of Indonesian Clinical Laboratory
Market”
Key Take Away :
Clinical Laboratory is one of the fastest growing segment in the healthcare industry driven via:
• Increasing individual health spending driven by Ageing population
• Rising number of development of rapid and widespread testing through improvement in clinical diagnostics
Page 10
Building a Multi-Tier Lab and Clinic Ecosystem for Strategic
Growth
Diagnos Is Evolving into a Comprehensive Healthcare Ecosystem. Leveraging tiered model of
clinics, labs, and diagnostics referral acquisitions, anchored by our national center of excellence
How Diagnos Multi-Tiered Ecosystem of Clinics & Lab
Empower Each Other
Top Tier :
National Centers of Excellence External Lab Partners
Outlet
Gen
CP
CEX
Test IDPT
CPX
Ref. Lab
Test
CPX
Ref.
Oncology National
Molecular Reference
Centers Laboratory
CPT MTG
Mid Tier : Oncology National
Community Occupational
Specialized Clinics Clinic Clinic Center Ref Lab
Independent Laboratories
Foundational Layer: Clinic
Third Party Clinics & Hospitals Strategic Clinic
Specialized Clinics Occ.
Comm
Partnership / Acquisitions Through Health
Health
• Laboratory Outlet Development
• Diagnostics Test Referral System
Page 11
Integrating Genetics Testing and Advanced Smart Medical
Checkup Within Community Clinic Service Offering
Comprehensive Customized Treatment Continuous Monitoring and
Genetic Screening Protocol Treatment Improvement
Powered By
Customizations and Personalized Health
Programs
• Genetic Markers for Dietary Response
• Optimized Exercise Programs
• Screening Based on Personalized Health
Risks
Genetics Driven Screening to
understand:
Innovative Treatment through Collection of
Cohort Data:
• Personal Attribute Predispositions
to various Chronic Diseases • Development of internal Clinical data
registry for robust data collection and
• Precision Diagnostics and Health analysis
Conditions based on Risk Profile
• Refinement of treatment protocols
through cohort study using genetics profile
& Phenotype Data
Page 12
Diagnos Healthcare Clinic Value Chain Creation : Delivering Comprehensive
Healthcare Excellence
Doctor Consultation Nutritionist Psychology Genomic Test Nutrigenomic &
Vit & Vaccine Injection Consultation Consultation For Productivity Healthy Food
Providing company-managed 2
care services to follow up on Corporate
health examination results and Managed Care
improve the quality of employee
health
Value Chain
Exercise Class
Body Health WhatsApp Group
(Aerobic/ Yoga/
Composition Talk Health Assistance
Zumba/ Body
Measurement
Combat) Material
Monitoring
Promotion
Corporate Personal Report Personal Health
Summary Report Risk Score Report
Medical Check Up service is
supported by AI-based Smart
1 Medical Report to provide Personal
Check Up Health Risk Score information
3
for the next 10 years based on
Inhouse Clinic the results of a doctor's
physical examination,
laboratory and radiology.
Environtmental Monitoring :
• Determining potential hazards
Developing Corporate • Mapping potential hazards based on location and
Inhouse Clinic based 4 intensity/level
company requirement Environtmental Environtmental Assesment :
to increase employee HCP Management : Integrated Clinic Monitoring • Indoor Air Quality
productivity & healthy Doctor & Nurse Management System & • Noise Mapping
: Electronic Medical
working environment Clinic Management : • Measurement of chemicals in the air
Equipment & Supplies Record, Laboratory • Heat Stress Examination
Order
Page 13
New Laboratory and Clinic Sites for Extended Service Coverage
DIAGNOS 2024 EXPANSION ROAD MAP, PIPELINE AND TARGET
Diagnos HealthCare - Community Clinic
Located in the business heart of Makassar City and within reach of residential areas,
with about 10 Healthcare provider located within 5km in proximity of the locations
Diagnos Healthcare - Occupancy Clinic • In Collaboration with Admedika, Fullerton and Halodoc for Payor, BGP for
Located in the business heart of Batam City to serve the Pharma, Klinik Pintar for Clinic Operations (TBC).
general medical checkup business opportunity in Batam
Area
Diagnos Pathalogy Anatomy Laboratory – Ciputat
• Located on the 4th floor of The Current Ciputat
branch of Diagnos, established to cater all the
Low-Cost / BPJS PA test demand from Bunda
Ciputat and Bunda Margonda and 3rd Party
Corporate MCU Clients
BATAM BRANCH • In Collaboration with RS Bunda Ciputat &
Bunda Groups Hospital
MAKASSAR BRANCH
Diagnos Healthcare – Occupancy Clinic
• Located on the 1st floor of Diagnos Tower to serve medical
checkup for premium corporate client and clinical license to JAKARTA BRANCH
cater for Project-based/Low-Cost Medical Checkup of Diagnos
Corporate Clients
• In Collaboration with Admedika, Fullterton and Halodoc for
Payor, BGP for Pharma, Klinik Pintar for Clinic Operations
(TBC)
Diagnos National Reference Laboratory
• Located on the 3rd and 4th floor of Diagnos Tower to
consolidate internal Diagnos volume to achieve bigger
economies of scale and lower cost of operations and better
environment for future product research and new product
development and simultaneously eliminating the unnecessary
Page 14
FINANCIAL PERFORMANCE
FY 2023
3Q 2024
14
Page 15
COMPREHENSIVE DIAGNOS TEST OFFERING DETAILS
DIAGNOS TOTAL TEST OFFERING OVER THE YEAR Key Points
Total Test (x) • Genomic contribution to Total Revenue has
been increasing in-line with our commercial
efforts to push market awareness, hence, the
average YTD 2024 of 18% contribution from
previous year of 15%.
• As of 3Q 2024 we run 25 Outlets across
Indonesia, ranging from Sumatra to Sulawesi
region.
DIAGNOS GENOMIC TEST OFFERING OVER THE YEAR
888,033
Test (x)
766,162
685,701
2,405
546,313
1,670
175,207 205,170 206,509
1,057
765 852
660 604
2020 2021 2022 2023 3Q 2023 2Q 2024 3Q 2024
2020 2021 2022 2023 3Q 2023 2Q 2024 3Q 2024
Page 16
DIAGNOS OVERALL REVENUE DEVELOPMENT & SOURCES
DIAGNOS Revenue Trend DIAGNOS 3Q 2024 Revenue Breakdown
Total Revenue (IDR Mn)
6.1%
22.8%
302,182
71.2%
183,171 192,886
145,696 39,300 42,310
35,903
2020 2021 2022 2023 3Q 2023 2Q 2024 3Q 2024 Doctor Referrals Corporate Clients
Walk in Customers
16
Page 17
DIAGNOS GROSS PROFIT & NET PROFIT PROFILE
DIAGNOS Gross Profit & Gross Margin DIAGNOS Net Profit & Net Margin
Gross profit Gross Margin Net profit Net Margin
60.0% 35.0%
28.8% 30.0%
49.8% 49.3%
47.3% 50.0%
43.5% 43.0% 25.0%
41.0% 39.9% 21.3%
40.0% 20.0%
15.0%
30.0% 6.6%
10.0%
20.0% 5.0%
(8.1%) 2.4% (1.6%)
0.0%
10.0% 53 64 13 (14) (3) 1 -1
(5.0%)
87 151 95 60 14 17 18 2020 2021 2022 2023 3Q 2Q 3Q
0.0% 2023 2024 2024 (10.0%)
2020 2021 2022 2023 3Q 2Q 3Q (9.4%)
2023 2024 2024 17
(15.0%)
Page 18
Thank You Contact Us Dessy Lapagu (Head of Corporate Finance & Investor Relation) +62817-0877-749 / dessy.lapagu@diagnos.co.id
Names mentioned 2 people and organisations named in the text · linked when the evidence is strong
unresolved
org
PT Diagnos Laboratorium Utama Clinics
p.4
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.